Tuesday, April 28, 2015

Donald Yacktman Buys Financials

The Yackman Focused Fund and the Yacktman Fund appreciated 7.41% and 7.3% in a 2011, while the S&P 500 closed up 2.11%, and, according to the Wall Street Journal, the average diversified U.S. stock fund declined 2.9%. Donald Yacktman anchored his fund in solid, large-cap companies that helped it to withstand the market's extreme volatility. The return was a decent addition to his track record, which has a five-year cumulative return of 47.2% compared to the S&P's negative 3.1%, and a ten-year cumulative of 174.5% compared the S&P's 32.1.

While Yacktman may have entered the financial scene, he is still doing it differently than, for instance, Bruce Berkowitz, by taking smaller positions, cautious of the continuing uncertainty. On Consuelo Mack in January he said, "The outcomes can be much wider. The array of outcomes. In other words, you could have a real disaster or you could have a spectacular upside. So as the array is wider, you end up attaching a probabilities to those outcomes, come up with a centrist rate of return, and then you want that to be quite a bit higher that what a normal rate of return would be based on the risk."

Yacktman released his fourth-quarter buys and sells on Wednesday, according to GuruFocus' Real Time Picks. His three largest buys are Goldman Sachs Group Inc. (GS), Bank of America Corp. (BAC) and State Street Corp. (STT).

Goldman Sachs Group Inc. (GS)

Goldman Sachs is a global investment banking and securities firm, providing a full range of investing, advisory and financing services worldwide to a substantial and diversified client base, which includes corporations, financial institutions, governments, and high net worth individuals. The Goldman Sachs Group Inc. has a market cap of $54.88 billion; its shares were traded at around $111.47 with a P/E ratio of 25.3 and P/S ratio of 1.9. The dividend yield of The Goldman Sachs Group Inc. stocks is 1.3%. The Goldman Sachs Group Inc. had an annual average earnings growth of 9.8% over the pa! st 10 years.

Yacktman bought 647,000 shares of Goldman Sachs in the fourth quarter at an average price of $97.50. Yactkman has said that his firm makes their top conviction ideas their largest positions, and buys smaller amounts of stocks they feel are of lesser quality. This one makes up 0.5% of his 64-stock portfolio.

Goldman Sachs stock price declined more than 31% in the last year, but year to date has already advanced 25.5%. Yacktman got the stock at a major discount. Its 52-week low was $84.27 per share, slightly higher than its recession low around $53 per share in 2008. Even after the recession it has recovered to around $190, with a 52-week high of $169.90.

For the last four years, Goldman Sachs' revenue has been declining. It was at $88 billion in 2007, with earnings of $11.6 billion, but ended 2011 with revenues of $28.81 billion, and earnings of $4.4 billion. Its financial results for the year showed declines in many areas of its business, including a return on average common shareholders' equity that slipped to 3.7% from 10.8% in 2010.

The firm attributed the decline in results to global macro-economic concerns which "significantly affected our clients' risk tolerance and willingness to transact," according to Lloyd Blankfein, chairman and CEO. Meanwhile, it did keep some industry-leading positions. It continued to rank first in worldwide announced mergers and acquisitions for the calendar year; ranked first in worldwide equity and equity-related offerings, common stock offerings and initial public offerings; achieved global core excess liquidity of $172 billion; and achieved a Tier 1 capital ratio under Basel I of 13.8%, unchanged from the previous quarter.

During the year, it also repurchased 47 million shares of its stock at an average cost per share of $128, at a total cost of $6.04 billion, and will pay a dividend of $0.35 per share on March 1, 2012.

Bank of America Corp. (BAC)

Bank of America Corp. is one of the world's financia! l service! s companies. Bank Of America Corp. has a market cap of $72.26 billion; its shares were traded at around $7.13 with and P/S ratio of 0.6. The dividend yield of Bank Of America Corp. stocks is 0.6%.

Bank of America is also a relatively small holding of Yacktman, comprising 0.25% of his portfolio. He sold out of his previous position in the bank just before its stock plunged in 2011. In the fourth quarter, he bought 5,565,000 shares at an average of $6 per share, already realizing a 20% return.

The last several years were challenging for Bank of America. Their revenue has been declining for the last three years, from $150.5 billion in 2009 to $115 billion in 2011. Net income, however, increased to $1.5 billion in 2011 from a loss of $2.2 billion in 2010, though still its lowest profit in the last 10 years.

On Wednesday, Bloomberg reported that the bank lost about three-quarters of its market share in U.S. home mortgages since 2007, due largely to defective loans. Its share of originations dropped to 5.6% in the fourth quarter, from 10 percent in the third quarter, and 24.7% in 2007.

State Street Corp. (STT)

State Street Corporation is the world's specialist in providing sophisticated global investors with investment servicing, investment management, investment research and trading services. State Street Corp. has a market cap of $19.27 billion; its shares were traded at around $39.18 with a P/E ratio of 10.3 and P/S ratio of 2. The dividend yield of State Street Corp. stocks is 1.9%. State Street Corp. had an annual average earnings growth of 6.9% over the past 10 years.

Yacktman bought 563,000 shares of State Street Corp. in the fourth quarter at an average price of $38, representing 0.19% of his portfolio.

In many ways, State Street Corp. is faring better than Yacktman's other financials. It has been increasing revenue each year for the past three years, from $9.4 billion in 2009 to $10.2 billion in 2011. Net income in 2011 increased to almost $2 billion, a! record. ! It also reinstated a dividend of $0.72 per share in 2011, after cutting it to $0.04 per share in 2009 and 2010. Prior to the cut, in 2008, the dividend was $0.95 per share.

The company recorded $120 million in restructuring charges for severance-related costs for reducing its workforce, withdrawing from its fixed-income trading initiative, and for expanding its IT infrastructure.

State Street is also planning to start actively managed exchange-traded funds, in partnership with other asset managers, such as Blackstone.

CEO Joseph Hooley has also predicted weak capital markets continuing into 2012. "I'm not trying to give necessarily a negative outlook, just a realistic outlook," Hooley said during a conference call with investors. "I don't think anybody's ready to predict that the most recent markets are going to sustain themselves."

Banks are difficult to understand, not least when they are trying to rebuild after a recession. Yacktman may believe the industry is nearing a bottom, however, and will lose far less than Bruce Berkowitz, who got in too early.

For more of Donald Yacktman's buys and sells, go here. Also check out the Undervalued Stocks, Top Growth Companies, and High Yield stocks of Donald Yacktman.

Monday, April 20, 2015

Cresud: Rare Value in Farmland

Argentina's largest farmland owner, owning more than 2.4 million acres, is a rare value, says Ian Wyatt of High Yield Wealth.

Cresud SA (CRESY) has 66% of those acres in Argentina; the rest are scattered through Brazil, Paraguay and Bolivia. In addition, it has extensive commercial property holdings in Buenos Aires.

Cresud CRESY is an exceptional value thanks to its depressed share price. For this, we can thank Argentina's dysfunctional government, led by President Christina Kirchner, who has overseen capital controls, foreign-owned asset seizures, and trade restrictions.

Investors, not surprisingly, are leery about investing in such a hostile political climate. But where other investors see fear, I see opportunity. I believe Ms. Kirchner has handed investors a gift.

Keep in mind-she won't be around forever. In fact, she may not be around past the October elections, as a backlash has set-in among her own supporters. In the meantime, I suggest investors focus on the value proposition. You know, see the forest through the trees.

The company has a proven record of growing revenue, cash flow and assets. Revenue over the past five years has soared to $665 million from $41 million, EBITDA per share has grown to $2.88 from $0.25 and book value per share has more than doubled to $11.70 from $5.

The value proposition is that Cresud offers the opportunity to invest in one of world's larger farmland owners at a 35% discount to book value.

The shares have historically traded at a premium to book value-frequently three to four times book value. Throw in the annual dividend, which yields 6%, and you have a unique value proposition in a popular asset class.

Keep in mind that Cresud has been around for more than 70 years, so the company has plenty of experience stepping around political minefields.

I fully expect that long after Ms. Kirchner has withdrawn from the political landscape, Cresud will still be plowing fields and raising cattle on Argentina's high plains.

Subscribe to Daily Profit here…

More from MoneyShow.com:

Brazilian Bets

Copa Holdings: Panama Profits

Finding the World's Best Growth Stocks

Thursday, April 16, 2015

Why FLIR Shares Flew

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of FLIR Systems (NASDAQ: FLIR  ) have steadily risen throughout the day, and are now sitting on gains of nearly 11% as of this writing, after reporting earnings this morning that primarily showed strength on the top line.

So what: FLIR's second-quarter revenue came in 15% higher year over year with a final result of $389.3 million, which was a fair bit ahead of the analyst consensus of $364.9 million. However, earnings of $0.35 per share were underwhelming, as Wall Street sought $0.37 per share for the quarter. The company's full-year guidance, which projects $1.5 billion-$1.6 billion on the top line and $1.56-$1.66 in EPS, doesn't exactly smash through consensus top- and bottom-line expectations of $1.5 billion and $1.64, respectively.

Now what: Investors may simply be breathing a sigh of relief over FLIR's ability to withstand the impact of the government sequester that was widely feared to hit many government contractors. The company's government systems backlog grew 5% year over year, which indicates some remaining strength where many might have not seen it. However, after the recent bounce, FLIR is nearing highs last reached in 2011, and the report was only good enough for S&P to raise its price target to $32 per share -- slightly lower than where shares traded as of this writing. A patent infringement suit that was filed today also puts a few clouds on FLIR's horizon. Step lightly into this stock, if you decide to step in at all.

Want more news and updates? Add FLIR to your Watchlist now.

Tuesday, April 14, 2015

Is this Diabetes Drug Class Poised for Disruption?

The Motley Fool's health care show "Market Checkup" focuses this week on diabetes, one of America's growing health care concerns. There are 2 versions of this chonic disease -- the more prevalent being type 2 diabetes, which makes up about 95% of all cases. Because of that overwhelming patient population, type 2 diabetes receives the majority of attention from big pharma companies.

Diabetes is no small problem. In 2010, one in 10 adults has diabetes, and more troubling, more than one in four senior citizens, making it the seventh leading cause of death. There are 2 million new cases in America per year, leading analysts to project spending on diabetes to approach $60 billion in just five years. And this isn't just an American problem; 370 million suffer from diabetes around the world.

In this video, health care analysts David Williamson and Max Macaluso discuss one of the prominent diabetes drug classes, highlighting both the major players and whether a new drug from Eli Lilly  (NYSE: LLY  ) will disrupt the current standard of care.

Rising health care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health care system -- and how to potentially profit from this trend -- click here for free, immediate access.

Follow David on Twitter: @MotleyDavid.